Antitrust Issues in Life Science

LathamStackedLogoRecent court cases dealing with antitrust issues in both the US and international markets provide valuable guidance.

Latham and Watkins, the law firm, provides a very content-rich webinar on this topic.

Please click here to go to the webinar signup page (registration required).

Webinar Introduction by Latham & Watkins

In this 60-minute complimentary webcast, a team of Latham & Watkins antitrust partners with experience at the FTC, DOJ and litigating novel and complex nationwide cases at the intersection of Antitrust and IP will discuss the key takeaways from these and other recent important events in the US and in Europe and what to look out for going forward.

Over the last month, there have been several significant developments relating to antitrust enforcement in the pharmaceutical and biotech sectors, including the $1.2 billion settlement of the FTC’s Cephalon pay-for-delay case, the California Supreme Court’s revival of the pay-for-delay litigation in In re Cipro I & II and the Second Circuit’s decision upholding the preliminary injunction the New York v. Actavis product hopping litigation. These events, plus the DOJ’s ongoing criminal investigation into the pharma sector and the other post-Actavis cases that address the interplay between antitrust law, IP rights, the Hatch-Waxman Act, and the FDA process, underscore the importance of staying on top of antitrust issues in the life sciences industry.